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Cataract Surgery combined with excimer laser
trabeculotomy to lower intraocular pressure:
effectiveness dependent on preoperative IOP
Marc Töteberg-Harms1,2*, James VM Hanson2 and Jens Funk2
Abstract
Background: Cataract surgery combined with excimer laser trabeculotomy (phaco-ELT) can reduce intraocular
pressure (IOP). The aim of this study was to evaluate the effect of phaco-ELT on IOP in patients as a function of
preoperative IOP.
Methods: Patients with open-angle glacuoma or ocular hypertension who received phaco-ELT between 01/2008
and 10/2009 were included. Patients were assigned based on preoperative IOP either to the study group
(≤21 mmHg) or control group (>21 mmHg) in this IRB-approved, prospective, consecutive case series. Visual Acuity,
IOP, and number of anti-glaucoma drugs (AGD) were recorded at baseline and 12 months after phaco-ELT. Any
postoperative complications were also recorded.
Results: 64 eyes of 64 patients (76.5 ± 9.4 years) were included. Baseline IOP was 19.8 ± 5.3 mmHg (AGD 2.4 ± 1.1)
for all eyes, 16.5 ± 2.9 mmHg (AGD 2.5 ± 1.0) for the study group, and 25.8 ± 2.9 mmHg (AGD 2.2 ± 1.4) for the
control group. Across the two groups, IOP was reduced by 4.5 ± 5.9 mmHg (-23.0%, p < 0.001) and AGD by 0.9 ± 1.5
(-38.9%, p < 0.001). For the study group IOP was reduced by 1.9 ± 4.4 mmHg (-11. 5 %, p = 0.012) and AGD by
1.1 ± 1.4 (-42.9%, p < 0.001), and for the control group by 9.5 ± 5.4 mmHg (-36.6%, p < 0.001) and AGD by 0.7 ± 1.6
(-29.5%, p = 0.085). There were no serious postoperative complications such as endophthalmitis, significant
hyphema, or a severe fibrinous reaction of the anterior chamber.
Conclusions: IOP remained significantly reduced from baseline 12 months after phaco-ELT regardless of
preoperative IOP levels, with no major complications. The IOP reduction remained constant over the entire follow-
up. Hence, phaco-ELT can be considered in glaucoma and ocular hypertensive patients whenever cataract surgery
is performed, in order to further reduce IOP or to reduce the requirement for IOP-reducing medications.
Keywords: Cataract, Cataract surgery, Extracapsular cataract extraction, Phacoemulsification, Glaucoma, Glaucoma
surgery, Excimer laser trabeculotomy, Excimer laser trabeculostomy, Trabecular meshwork, Primary open angle
glaucoma, Ocular hypertension
Background
Glaucoma is a widespread disease leading to progressive loss
of visual function and remains one of the leading causes of
irreversible blindness around the world. In managing glau-
coma patients, the goal of IOP reduction remains the only
therapeutic approach supported by a significant evidence
base [1-6]. Treatment often begins with topical medications.
If IOP remains insufficiently controlled, several surgical pro-
cedures are available in order to further reduce IOP.
Trabeculectomy remains the gold standard in glaucoma sur-
gery [7] and is very effective in long-term reduction of IOP.
However, trabeculectomy and other surgical glaucoma pro-
cedures have substantial disadvantages [8]. IOP elevation is
usually caused by reduced drainage of aqueous humor, whilst
aqueous production remains constant. The main location of
outflow resistance is likely to be the juxtacanalicular trabecu-
lar meshwork (TM) [9,10]. Therefore, the most physiologic-
ally feasible goal of any surgical procedure to reduce IOP is
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to improve trabecular outflow. Excimer laser trabeculotomy
(or excimer laser trabeculostomy, ELT) ab interno is one
minimally invasive surgical technique to reduce IOP in pa-
tients with glaucoma or ocular hypertension. ELT enhances
aqueous humor outflow into Schlemm’s canal and its drain-
age against the episcleral vein pressure by creating channels
from the anterior chamber through the TM and inner wall
of Schlemm’s canal [11-24]. It is not usually possible to re-
duce IOP to the same level as achieved through fistulating
surgery. However, the ELT technique is one that can be
quickly acquired by ophthalmic surgeons, especially cataract
surgeons. ELT is relatively safe in combination with cataract
surgery and can lower IOP to a greater degree than that
achieved by cataract extraction alone [20]. The potential to
reduce IOP in patients with elevated pre-operative IOP
(>21 mmHg) has been previously investigated. However, the
comparative effectiveness of combined phacoemulsification
and ELT in patients with lower pre-operative IOP remains
unclear. The aim of this study was therefore to evaluate
whether phaco-ELT is also effective in lowering the IOP in
eyes with IOP ≤21 mmHg. To investigate this question two
groups of patients were evaluated: one with a preoperative
IOP of ≤21 mmHg (study group), and a second with a pre-
operative IOP of >21 mmHg (control group).
Methods
Included in this prospective, single-center case-series
were consecutive patients who underwent clear cornea
extracapsular cataract extraction by phacoemulsification
and intracapsular lens implantation combined with ELT
(phaco-ELT) between 01/2008 and 10/2009. If both eyes
of a patient underwent phaco-ELT, only the eye that was
operated first was included in the study; thus, 9 eyes were
excluded. Patients were followed-up at 12 months ± 2
weeks after the procedure. All subjects were recruited
from the ophthalmological out-patient department and
gave prior written informed consent. The study was ap-
proved by the local ethics committee (Ethics Committee
of the Canton Zurich, KEK-ZH-Nr. 881, 06/07/2009) and
adhered to the tenets of the Declaration of Helsinki and
local law. The study is registered in the clinical trials regis-
try of the U.S. National Institutes of Health (http://www.
clinicaltrials.gov, NCT01194310). Intraocular pressure
(using Goldmann applanation tonometry), best corrected
visual acuity (BCVA, using Snellen charts), slit lamp
biomicroscopy of the anterior and posterior segment as
well as glaucoma medication history were documented by
one examiner (M. T.-H.). The indications for a combined
phaco-ELT intervention were the presence of a visually
significant cataract (BCVA less than or equal to 0.5
Snellen) and a moderately elevated IOP in the absence of
medical therapy, or a moderate cataract (BCVA less than
or equal to 0.8 Snellen) and uncontrolled IOP despite
medical therapy.
Inclusion/exclusion criteria
Inclusion criteria were a diagnosis of ocular hyperten-
sion or manifest glaucoma with typical glaucomatous
cupping of the optic disc, visual field changes, or both,
together with an open iridocorneal angle (grade 3 or 4
on the Shaffer scale [25]). Patients with advanced glau-
coma (i.e., fixation-threatening visual-field defects) or
with an IOP ≥35 mmHg were excluded. Patients with a
history of optic neuropathies other than glaucoma were
also excluded.
Surgical procedure
All surgeries were performed by the same surgeon
(J. F.). A standard clear-cornea phacoemulsification and
intracapsular lens implantation (Alcon MA 50 BM,
Alcon Inc., Hünenberg, Switzerland) was performed. Im-
mediately afterwards, a medical miosis was induced by
acetylcholine chloride (Miochol) and the anterior cham-
ber was deepened with viscoelastic (sodium hyaluronate,
Healon). An endoscopically-guided photoablative laser
operating at a wavelength of 308 nm (excimer laser,
AIDA, TUI-Laser, Munich, Germany) was used to create
ten microperforations (ELT channels) into the trabecular
meshwork spread over an area of 90°. Each ELT channel
was approximately 0.2 mm in diameter. Further details
of the laser device are provided in Table 1. In order to
transmit adequate sub-threshold energy of the laser to
the target tissue, the instrument tip had to touch the
TM (see Figure 1). After laser application a formation of
bubbles was seen together with a small retrograde bleed-
ing, indicating the perforation of the trabecular mesh-
work and the inner wall of Schlemm’s canal (see
Figure 2). In all patients the bleeding resolved spontan-
eously. At the end of the surgical procedure, the visco-
elastic was washed out of the anterior chamber and the
globe was pressurized to approximately 15 mmHg. The
paracentesis and clear corneal incision were hydrated
with sterile balanced salt solution (BSS). Cefazolin and
Dexamethasone were injected subconjunctivally at the
end of the procedure. Intracameral endophthalmitis
Table 1 Technical data of the AIDA excimer laser
Laser type XeCl excimer laser, laser class 4
Wavelength 308 nm
Cooling Air
Pulse energy 1.2 mJ at fiber tip
Pulse duration 60 ns
Repetition rate 20 Hz
Laser spot size 200 μm
Cannula diameter 500 μm
Cannula material Stainless steel
Length of fiber 2,000 mm
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prophylaxis was not used because at the time of the
study no commercially available antibiotic solution was
certified or approved for this purpose, and because of
the risk of serious side effects (e.g. toxic anterior seg-
ment syndrome, anaphylaxis in patients with a history of
penicillin allergy). Combined Tobramycin and Dexa-
methasone ointment was applied and the eye was cov-
ered with an eye patch overnight. From the first
postoperative day, Tobramycin and Dexamethasone eye
drops (q.i.d.) and Tobramycin and Dexamethasone oint-
ment (at bedtime) were applied for 2 weeks. After the
second week, only the eye drops (three times daily) were
applied and reduced weekly by one drop.
Study endpoints
Primary study endpoints were IOP and number of
antiglaucoma drugs (AGD) taken. Secondary study end-
points were BCVA, intra- and postoperative complica-
tions, and the requirement for subsequent glaucoma
surgery.
Statistical analyses
Descriptive statistics for quantitative variables such as
mean, standard deviation, 95% confidence interval and
relative frequencies for qualitative variables were calcu-
lated for all study eyes (without dropouts) and for the
two subgroups separately – one with a preoperative IOP
of ≤21 mmHg (study group) and one with a preoperative
IOP of >21 mmHg (control group). Data are given as
arithmetic mean ± standard deviation. A student’s t test
was used for testing significant changes in IOP, BCVA
and number of AGD. The significance level was defined
by p < 0.05. For statistics (e.g. percentage change), BCVA
was transformed to logMAR values and retransformed
into Snellen for reporting of the results [26,27].
Additionally, the number of patients that met the suc-
cess criteria was calculated. Statistical analyses were
conducted in SPSS software version 19.0.0 for Macintosh
(IBM Corporation, New York, NY, USA).
Definition of success and failure
Success was defined based on the criteria from the Tube
Versus Trabeculectomy study (TVT study) [28] as post-
operative IOP below or equal to 21 mmHg and IOP re-
duction of at least 20%. In addition, the number of AGD
postoperatively had to be less than or equal to that
recorded preoperatively. Subsequent surgery within the
follow-up period (12 months) due to insufficient IOP re-
duction at the initial intervention was classified as treat-
ment failure.
Results
In total, 64 eyes of 64 consecutive patients with a mean
age of 76.5 ± 9.4 years were included. The demographical
data for all study eyes and the two groups is shown in
Table 2.
For all study eyes mean preoperative IOP was 19.8 ±
5.3 mmHg (95% confidence interval (CI) 18.4 – 21.2)
and the mean number of prescribed AGD was 2.4 ± 1.1
(95% CI 2.1 – 2.7). After phaco-ELT, mean IOP was
15.2 ± 4.4 mmHg (95% CI 14.1 – 16.4) and an average of
1.5 ± 1.4 AGD (95% CI 1.1 – 1.8) were prescribed (see
Table 3). Comparing the preoperative and postoperative
IOP, there was a reduction of 4.5 ± 5.9 mmHg (-23.0%,
95% CI 3.0 – 6.1, p < 0.001) and a reduction in the num-
ber of required AGD of 0.9 ± 1.5 (-38.9%, 95% CI 0.5 –
1.3, p < 0.001; see Table 4).
Figure 1 Under endoscopic guidance, ten laser spots were
applied into the trabecular meshwork spread over an area of
90°. At the point of laser transmission, the probe is in direct contact
with the trabecular meshwork.
Figure 2 After laser application a formation of bubbles could
be seen, together with a small retrograde bleeding.
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Analyzing the study group (preoperative IOP
≤21 mmHg), the mean preoperative IOP was 16.5 ±
2.9 mmHg (95% CI 15.5 – 17.5) and a mean of 2.5 ± 1.0
AGD (95% CI 2.2 – 2.8) was recorded before treatment.
After phaco-ELT, mean IOP was 14.6 ± 3.7 mmHg (95%
CI 13.4 – 15.9) and an average of 1.4 ± 1.3 AGD (95% CI
1.0 – 1.8) were required (see Table 3). Comparing the
preoperative and postoperative IOP, there was a reduc-
tion of 1.9 ± 4.4 mmHg (-11.5%, 95% CI 0.4 – 3.3,
p = 0.012), and a reduction in the number of prescribed
AGD of 1.1 ± 1.4 (-42.9%, 95% CI -0.6 – 1.5, p < 0.001;
see Table 4).
Analyzing the control group (preoperative IOP
>21 mmHg), the mean preoperative IOP was 25.8 ±
2.9 mmHg (95% CI 24.5 – 27.1) and the mean of pre-
scribed AGD was 2.2 ± 1.4 (95% CI 1.6 – 2.8). After
phaco-ELT the mean IOP in this group was 16.4 ±
5.4 mmHg (95% CI 13.9 – 18.9) and an average of 1.6 ±
1.5 AGD (95% CI 0.9 – 2.2) were required (see Table 3).
Comparing the preoperative and postoperative IOP,
there was a reduction of 9.5 ± 5.4 mmHg (-36.6%, 95%
CI 6.9 – 12.0, p < 0.001), and a reduction in the number
of required AGD of 0.7 ± 1.6 (-29.5% 95% CI 0.1 – 1.4,
p = 0.085; see Table 4).
Preoperative BCVA was 0.4 ± 0.2 Snellen, which im-
proved significantly after cataract surgery (p < 0.001) for
all study eyes to 0.7 ± 0.3 Snellen and in the study and
control groups from 0.4 ± 0.2 to 0.7 ± 0.3 and from 0.4 ±
0.3 to 0.8 ± 0.3, respectively (see Table 3).
Seven eyes needed further glaucoma surgery to control
the IOP within the 12-month follow-up period and were
thus classified as treatment failures when calculating the
success-rate (see Table 5). After the follow-up period of
12 months 30 out of 64 eyes (46.9%) met the criteria of
success. In the study group 15 out of 40 eyes (37.5%)
and in the control group 15 out of 24 eyes (62.5%) met
the criteria of success.
Only a few patients showed a mild anterior chamber
reaction, as is often seen after cataract surgery. No pa-
tients suffered from serious postoperative complications
such as endophthalmitis, significant hyphema, or a se-
vere fibrinous reaction of the anterior chamber.
Discussion
The study confirmed a reduction in IOP, regardless of
preoperative value, and a reduction in AGD after the
follow-up period of 12 months. IOP for all study eyes
was reduced from 19.8 ± 5.3 mmHg at baseline by -4.5 ±
5.9 mmHg (-23.0%; P < 0.001) and at the same time the
average number of required AGD was reduced from 2.4
± 1.1 by nearly one medication (-0.9 ± 1.5; -38.9%;
P < 0.001). The study group (preoperative IOP ≤21 mmHg)
showed a reduction in IOP from 16.5 ± 2.9 mmHg at
baseline of -1.9 ± 4.4 mmHg (-11.5%; P = 0.012), whilst at
the same time AGD could be reduced from 2.5 ± 1.0 by
-1.1 ± 1.4 (-42.9%; P < 0.001). The control group (pre-
operative IOP >21 mmHg) showed a reduction in IOP
from 25.8 ± 2.9 mmHg at baseline of -9.5 ± 5.4 mmHg
(-36.6%; P < 0.001), whilst at the same time AGD could
be reduced from 2.2 ± 1.4 by -0.7 ± 1.6 (-29.5%;
P = 0.085). The reduction of AGD in the control group
tended toward, but did not reach, statistical significance.
Excimer laser trabeculectomy is easy to perform at the
end of a clear-cornea extracapsular cataract extraction
by phacoemulsification. Duration of cataract surgery is
only prolonged by 2 – 3 minutes for the excimer laser
trabeculotomy and, as the same clear corneal incision as
for phacoemulsification is also used for ELT, no add-
itional incision is required. For an experienced cataract
surgeon, ELT is usually a very easy technique to learn. In
general, dealing with the endoscope is very simple, and
identification of TM is much simpler with the endoscope
than with a gonioscopy lens at the slit lamp.
Using energy with a wavelength of 308 nm, the trabecular
meshwork is gently ablated and microperforations between
the anterior chamber and Schlemm’s canal are created (ELT
channels) [16,29,30]. There are almost no thermal side ef-
fects or damage of the outer wall of Schlemm’s canal. Dur-
ing ablation, the TM tissue is vaporized into gas; the
expanding gas has the effect of cooling the tissue and thus
limiting thermal damage.
Table 2 Demographic data
Number of study eyes 64 (26 right and 40 left eyes)
from 64 patients
mean age 76.5 ± 9.4 years
gender 22 males (34.4%) / 42 females
(65.6%)
Diagnosis: no. of patients
primary open angle glaucoma 21 (32.8%)
pseudoexfoliative glaucoma 37 (57.8%)
normal-tension glaucoma 2 (3.1%)
ocular hypertension 4 (6.3%)
Study group (IOP pre phaco-ELT
≤21mmHg):
Number of eyes 40 (13 right and 27 left eyes) from
40 patients
mean age 79.2 ± 7.4 years
gender 15 males (37.5%) / 25 females
(62.5%)
Control group (IOP pre phaco-ELT
>21mmHg):
Number of eyes 24 (11 right and 13 left eyes) from
24 patients
mean age 74.9 ± 12.2 years
gender 9 males (37.5%) / 15 females (62.5%)
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Table 3 Statistical data of BCVA (Snellen), IOP (mmHg) and AGD (numbers) pre and post phaco-ELT
BCVA IOP AGD
Pre Post Pre Post Pre Post
Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI
All 0.4 ± 0.2 0.4 – 0.5 0.7 ± 0.3 0.7 – 0.8 19.8 ± 5.3 18.4 – 21.2 15.2 ± 4. 4 14.1 – 16.4 2.4 ± 1.1 2.1 – 2.7 1.5 ± 1.4 1.1 – 1.8
Study group 0.4 ± 0.2 0.3 – 0.5 0.7 ± 0.3 0.7 – 0.8 16.5 ± 2.9 15.5 – 17.5 14.6 ± 3.7 13.4 – 15.9 2.5 ± 1.0 2.2 – 2.8 1.4 ± 1.3 1.0 – 1.8
Control group 0.4 ± 0.3 0.3 – 0.5 0.8 ± 0.3 0.6 – 0.9 25.8 ± 2.9 24.5 – 27.1 16.4 ± 5.4 13.9 – 18.9 2.2 ± 1.4 1.6 – 2.8 1.6 ± 1.5 0.9 – 2.2
Abbreviations: pre before phaco-ELT, post 12 months after phaco-ELT, SD standard deviation, CI confidence interval.
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The punctal ablation of TM by an excimer laser was first
developed and evaluated under laboratory conditions in
1987 by Berlin and colleagues [31,32]. In 1996 results of the
technique in humans were published by Vogel et al [16].
Vogel and colleagues used a laser prototype and the laser
application was monitored using a contact glass. The ELT
technique differs substantially from other minimally-
invasive anti-glaucoma laser techniques like ALT or SLT.
The latter techniques induce physical tissue alterations by
means of heat or a cellular tissue remodeling, respectively.
Because of this the IOP-lowering effect of ALT and SLT re-
duces over a period of months to years. After ELT, the edges
of the laser channels are found to be very smooth [16,18],
thus minimizing wound healing and contributing to a long-
lasting IOP reduction over years.
If it should subsequently be required, filtering surgery
is not compromised after ELT because there is no con-
junctival manipulation during surgery and therefore no
scarring or inflammation of the conjunctiva is induced
that would adversely influence the outcome of
trabeculectomy. In addition, ELT treats only 90° of the
TM. It is possible to repeat treatment in the remaining
three quadrants of the TM when primary treatment is
not sufficient.
In a previous study, we showed the success of phaco-
ELT in a smaller collective, who all had a preoperative
IOP >21 mmHg [33]. We found an average IOP de-
crease of 8.8 ± 5.3 mmHg (-34.7%, p < 0.001), and AGD
could be reduced by 0.8 ± 1.5 (-62.7%, p = 0.017) medica-
tions at the same time. This is in accordance with other
studies [19-21]. In this study we investigate if phaco-ELT
is also a feasible and effective option in patients with
lower preoperative IOP.
In the present study, we found a satisfactory IOP re-
duction in those eyes with lower IOP, although less than
that observed in those eyes with higher pre-operative
IOP (-1.9 mmHg, -11.5% in the study group vs. -9.5
mmHg, -36.6% in the control group). This could be
explained by the pressure gradient between the anterior
chamber and episcleral veins. As episcleral venous pres-
sure is nearly constant, the pressure gradient and the ef-
fect of phaco-ELT are directly dependent on IOP.
It is known that, when performed as a single procedure,
phacoemulsification has the effect of reducing IOP [34-38].
This is most likely due to the deepening of the chamber
angle by extracting the thickened opaque lens and subse-
quently enhanced drainage of aqueous humor. The IOP re-
duction following phaco-ELT is greater than that due solely
to cataract surgery. Thus, the IOP reduction we found fol-
lowing phaco-ELT is a combined effect of both the
phacoemulsification and the ELT. This has also been shown
by prior studies comparing ELT alone with phaco-ELT
[20,21]. Recently the Ocular Hypertension Treatment Study
(OHTS) group analyzed their data to assess the IOP-
lowering effect of cataract extraction. Their cataract group
had an IOP comparable to our control group. They found
an IOP decrease of 4.1 mmHg (16.5%) after cataract extrac-
tion, whereas the IOP remained unchanged in their control
group of patients who did not undergo cataract extraction.
We found an average IOP reduction of 9.5 mmHg (36.6%)
after phaco-ELT. It was also possible to reduce the AGD by
an average of 0.7 (29.5%). The combined effect of Phaco and
ELT markedly exceeds that of cataract extraction alone as
found by the OHTS group [39]. IOP fluctuation is a risk fac-
tor for glaucoma progression. Phacoemulsification may
lower IOP but may not have a substantial influence on IOP
fluctuation, whereas ELT may reduce diurnal IOP variation.
Possible effects on diurnal IOP are an issue worthy of exam-
ination in a future study.
We found a success rate of 46.9% for phaco-ELT after
12 months (62.5% for the control group). The success
rate for the control group is very similar to that previ-
ously published and for trabeculectomy by Mills and
Khalili et al. [40,41], which is remarkable considering the
minimally invasive nature of this technique. However,
success rates after trabeculectomy are mostly reported
Table 4 Increase in BCVA (Snellen) and reduction in IOP (mmHg) and AGD (numbers), comparing values pre to post
phaco-ELT
Mean ± SD Percentage Confidence Interval P Value
All eyes Δ BCVA (post-pre) +0.3 ± 0.3 +80.5 % 0.3 – 0.4 p < 0.001 *
Δ IOP (post-pre) −4.5 ± 5.9 mmHg −23.0 % 3.0 – 6.1 p < 0.001 *
Δ AGD (post-pre) −0.9 ± 1.5 −38.9 % 0.5 – 1.3 p < 0.001 *
Study group Δ BCVA (post-pre) +0.3 ± 0.3 +82.5 % 0.2 – 0.4 p < 0.001 *
Δ IOP (post-pre) −1.9 ± 4.4 mmHg −11.5 % 0.4 – 3.3 p = 0.012 *
Δ AGD (post-pre) −1.1 ± 1.4 −42.9 % 0.6 – 1.5 p < 0.001 *
Control group Δ BCVA (post-pre) +0.3 ± 0.3 +78.6 % 0.2 – 0.5 p < 0.001 *
Δ IOP (post-pre) −9.5 ± 5.4 mmHg −36.6 % 6.9 – 12.0 p < 0.001 *
Δ AGD (post-pre) −0.7 ± 1.6 −29.5 % 0.1 – 1.4 p = 0.085
Abbreviations: pre before phaco-ELT, post 12 month after phaco-ELT, SD standard deviation, * statistically significant.
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Table 5 Dropouts due to IOP-lowering surgery during follow up
Study-
no.
Date
of
birth
Gender Eye Diagnosis BCVA
pre
phaco-
ELT
IOP
pre
phaco-
ELT
AGD
pre
phaco-
ELT
Subsequent
surgery
Time to
Subsequent
surgery
[month]
BCVA pre
Subsequent
surgery
IOP pre
Subsequent
surgery
AGD pre
Subsequent
surgery
BCVA 1-3
month after
Subsequent
surgery
IOP 1-3
month after
Subsequent
surgery
AGD 1-3
month after
Subsequent
surgery
55 15/
07/
1941
F RE PEX 0.1 19 3 5x CPC 0.9 0.3 30 4 0.3 10 2
70 08/
09/
1930
F RE PEX HM 20 4 TE, SLT 3.5 0.6 30 1 0.4 28 4
38 06/
10/
1927
M RE PEX 0.2 23 3 TE 4.9 0.5 30 3 0.4 10 0
12 28/
10/
1934
F LE PEX 0.2 24 2 CPC 1.9 0.1 32 1 0.1 23 1
65 14/
05/
1947
M LE POAG 0.6 33 1 4x CPC, TE 1.1 0.1 34 4 0.1 15 1
42 14/
01/
1940
F LE PEX 0.4 36 4 CPC 0.9 0.5 30 5 0.6 18 1
49 11/
01/
1935
F LE PEX 0.1 17 3 CPC, 1x TA-IVI, 4x
Avastin-IVI (due to
Irvine-Gass
syndrome)
4.5 0.3 14 2 0.1 15 2
Abbreviations: RE right eye, LE left eye, VA Visual acuity, HM hand movements, pre before phaco-ELT, post 12 months ± 2 weeks after phaco-ELT, CPC trans-conjunctival cyclophotocoagulation, SLT selective laser
trabeculoplasty, TE trabeculotomy, TA triamcinolone acetate, IVI intravitreal injection.
Töteberg-H
arm
s
et
al.BM
C
O
phthalm
ology
2013,13:24
Page
7
of
9
http://w
w
w
.biom
edcentral.com
/1471-2415/13/24
without AGD whereas our success rates are with or without
AGD. After trabeculectomy, local antiglaucamatous medica-
tion would potentially compromise the long-term efficacy of
the filtering bleb by inducing inflammation and scarring.
After phaco-ELT, topical medications may be applied with-
out such a risk. Therefore, we do not classify medical treat-
ment after phaco-ELT as a treatment failure as long as the
number of medications is equal or less compared to the pre-
operative number.
A weakness of our study is the absence of a group
undergoing only phacoemulsification, to act as a further
control. The IOP-lowering effect of phaco has been
widely investigated. We are currently engaged in a study
following patient outcomes over five years and longer.
Included in this study are patients with a range of glau-
comas with different pathological mechanisms. The TM,
especially the juxtacanalicular region of TM, is known to
have the highest aqueous outflow resistance. This is the
major cause of elevated IOP in primary open angle glau-
coma. ELT bypasses this outflow pathway, as the aque-
ous humor is guided directly from the anterior chamber
into the collector channels. Therefore, the underlying
mechanism of the glaucoma is irrelevant as long as the
elevated IOP is caused by an elevated outflow resistance
in the TM.
Conclusion
For a selected collective of glaucoma or ocular hypertensive
patients with at least a moderate cataract and who do not
need the lowest target pressures, and in particular for those
with an IOP over 21 mmHg, the combined surgery of
excimer laser trabeculotomy and phacoemulsification (phaco-
ELT) seems to be a good way to avoid or at least to delay
trabeculectomy for some years. For patients with an IOP of
21 mmHg or lower, the addition of ELT to a standard cataract
surgery procedure is a good option to lower IOP and to save
AGD.
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